Bavarian Nordic to raise €387m to fund GSK vaccines purchase

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
Follow-ons and Rights issues

Bavarian Nordic to raise €387m to fund GSK vaccines purchase

Aidan Gregory
March 06, 2020 03:45 pm
Copenhagen_PA_575_375
February 8, 2015, Copenhagen, Capital Region of Denmark, Denmark: Nyhavn, The Famous Waterfront Canal In Copenhagen With Colourful Seventeenth And Eighteenth Century Townhomes Lining The Canal At Dusk; Copenhagen, Denmark (Credit Image: © Micah Wright/Design Pics via ZUMA Wire) | Micah Wright/Zuma Press/PA Images

Danish pharmaceuticals company Bavarian Nordic has announced an Nkr2.8bn (€378m) rights issue to fund its acquisition of GlaxoSmithKline’s commercial and manufacturing rights to Rabipur, a treatment for rabies, and Encepur, a vaccine against tick-borne encephalitis.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

NordicsHealth and BiotechDenmarkEquityEuropeFollow-ons and Rights issuesEMEASRINordea Markets
AG
Aidan Gregory
Gift this article